Technavio, a US-based global technology research and advisory company, announced on Thursday that the global autism spectrum disorder (ASD) therapeutics market size is expected to increase by USD766.1m from 2024 to 2028.
The market is likely to increase at a CAGR of 6.78% during the forecast period.
Increasing prevalence of asd is driving market growth, with a trend towards increasing interest in personalized medicine for treatment of ASD.
The main market players include ASSERTIO HOLDINGS INC., AutismSTEP, Bristol Myers Squibb Co., CureMark LLC, F. Hoffmann La Roche Ltd., Fraser, Jazz Pharmaceuticals Plc, Johnson and Johnson Services Inc., Les Laboratoires Servier, Neurim Pharmaceuticals Ltd., Novartis AG, Oryzon Genomics SA, Otsuka Holdings Co. Ltd., PaxMedica Inc., Q BioMed Inc., Scioto Biosciences Inc., Stalicla SA, Travere Therapeutics Inc., Yamo Pharmaceuticals LLC and Zynerba Pharmaceuticals Inc.
FDA extends Biohaven's PDUFA date for troriluzole NDA for spinocerebellar ataxia
AbbVie and ADARx Pharmaceuticals partner on next-generation siRNA therapies
Clarivate adds Pathway Maps to OFF-X, boosting drug safety intelligence
GSK to acquire efimosfermin in USD2bn deal to expand hepatology pipeline
Hemogenyx Pharmaceuticals expands HG-CT-1 trial to include paediatric AML patients
Cumberland Pharmaceuticals partners Qureight for idiopathic pulmonary fibrosis treatment research
Hoth Therapeutics reports positive HT-KIT preclinical results
Solve M.E. announces Dr Akiko Iwasaki as first recipient of inaugural ME/CFS Catalyst Award
DELFI Diagnostics CTO receives 2025 Most Influential Women in Bay Area Business recognition
RemeGen reports positive phase 3 results for disitamab vedotin in advanced urothelial carcinoma
Lilly and Purdue University expand collaboration, announce investment
AstraZeneca's Imfinzi improves disease-free survival in early bladder cancer trial